According to the requirement of subject structuring and specific development,this paper combine with the teaching experience of fermentology course to make a preliminary discussion about how to reform teaching material、teaching method and practice content.

Two monoclonal antibodies of anti-mouse pancreatic cancer, 2B_6and 2B~(10), were purified by the use of salt fractionation-exchange chromatography(DEAE-52) or affinity chromatography from culture supernatants and mice ascites of the hybridomas. After assayed by the use of SDS-PAGE and labeled with FITC, they were used to analyse related antigen site of 35 tissue samples of several human tumor by means of direct-fluorescence method. There was an intense positive reaction between 2B_(10)and 4 samples of gastric cancer. 2B_6or 2B_(10)and 3 tissur samples of ovary cancer and 1 clonal cell of ovary cancer also had intense positive reaction. These results showed that there exist common tumor antigen in both human and mice.

Objective: To explore the relationship between coxsackie-adenovirus receptor(CAR)expression and the infection efficiency of adenovirus vector in gene therapy for hepatocellular carcinoma through regulating CAR expression on cells surface via inhibition of the Raf/MEK/ERK pathway.Methods: Western blotting analysis was used to examine CAR expression in hepatocellular carcinoma cells(SMMC-7721 and HepG_2)before and after treatment with U0126,inhibitor of Raf/MEK/ERK signal transduetion.SMMC-7721 and HepG_2 were infected by a non-replicating,E1 A-deleted adenovirus expressing EGFP(Ad-GFP).FACS was used to analyze the infection efficiency of Ad before and after U0126 treatment. Results: The expression of CAR on cell surface had an increasing tendency after treatment with U0126.FACS analysis showed significantly increased infectivity of cells treated with the MEK inhibitor U0126 compared with untreated cells: SMMC-7721,(71.65?6.21)%→(86.54?5.70)%,HepG_2,(77.53?4.62)%→(87.06?2.83)%,when infected with Ad-GFP at the same MOI(10 MOI).Conclusion: The inhibition of Raf/MEK/ERK pathway by U0126 may up-regulate the expression of CAR in some hepatocellular carcinoma cells,which subsequently enhances the susceptibility of adenovirus infection to target cells.

Animals ; Disease Models, Animal ; Ischemic Preconditioning ; methods ; Lung ; blood supply ; Male ; Nitric Oxide Synthase ; metabolism ; Nitroarginine ; pharmacology ; Rabbits ; Reperfusion Injury ; metabolism

Astrocytes are the most abundant neuronal cells in the central nervous system.It plays an important physiological role.In the process of cerebral ischemia,astrocyte activation is one of the major changes in the central nervous system.The activated astrocytes can play a neuroprotective role through the mechanisms such as maintaining ionic balance,regulating energy metabolism,removing excitatory amino acids,against oxidative stress,and secreting neuroprotective substances.However,astrocyte activation after cerebral ischemia also has its disadvantage.This article reviews the neuroprotective and damage roles of astrocyte activation during cerebral ischemia.It also investigates its regulatory mechanisms in order to provide new ideas for the treatment of ischemic stroke.

Objective To investigate the effect of CD147 monoclonal antibody (mAb) on the natural resistance to paclitaxel (TAX) in the human cervical cancer line (HCE1) multicellular spheroid (HCE1/MCS) model and if CD147 mAb can reverse the HCE1/MCS resistance to TAX. Methods HCE1/MCS was obtained by liquid overlay and rotating technique. HCE1/MCS morphological changes were observed before or after the interference of CD147 mAb. The effects of TAX on HCE1/MCS (including inhibition ratio, IC50 and index of multicellular resistance) before or after CD147 mAb treatment were determined by the method of WST-1 and the inhibition ratio curve was mapped. Cell cycle and apoptosis were detected by flow cytometer (FCM). The expression of CD147 and P-gp of both HCE1/MC and HCE1/MCS was detected by immunocytochemistry. Results HCE1/MCS was established successfully. CD147 mAb could inhibit HCE1/MCS from forming spheroids. CD147 mAb could enhance the sensitivity of HCE1/MCS to TAX. IC50 in different concentrations of CD147 mAb (5,10,20 μg/mL) HCE1/MCS group were (40.31±3.73), (32.43±1.56), and (30.69±1.01) μg/mL. CD147 mAb resulted in G1/G0 arrest in HCE1/MCS. CD147 mAb of low concentrations (0-10 μg/mL) caused a dose-dependent inhibition of HCE1/MCS (P<0.05). Combined with TAX, CD147 mAb could also induce HCE1/MCS cell cycle arrest in both G1/S and G2/M stage. The expression of CD147 and P-gp was consistent in HCE1/MCS groups. Conclusion CD147 plays an important role in muliticellular resistance of cervical cancer and inhibition of CD147 can synergistically reverse the multicellular drug resistance (MCR) in cervical cancer. The MCR of HCE1/MCS mediated by CD147 is related to P-gp.

Pre-implantation Genetic Diagnosis(PGD) is an advanced technology based on in-vitro fertility-embryo transfer,which binds multiple-discipline arts,specially the research on DNA analysis assay of single cell,to reach the aim of aristogenesis and wash out abnormal embryo before transfer.With the development of this technique and the ever wider applications,ethical issues also arise.This paper focuses on these ethical issues related to PGD,expecting an actual benefit for human.

Objective The aim of this prospective randomized study was to compare the effects of remifentanil (R) and fentanyl (F) given by target-controlled infusion (TCI) on the Cp50 of TCI propofol for loss of consciousness ( LOC ) . Methods Sixty-four ASA 1 or II patients aged 20-55 yr undergoing elective cholecystectomy or mastectomy under general anesthesia were enrolled in this study. Their BMI ranged from 18-30 kg?m-2. The patients were randomly allocated to one of four groups with 16 patients in each group: (1) propofol alone (P), (2) P + remifentanil (Cp = 4 ?g?L-1 ) (R4), (3) P + remifentanil (Cp = 7 ?g?L 1 ) (R7) and (4) P + fentanyl (Cp = 4?g?L-1 ) (F). The patients were unpremeditated. Anesthesia was induced with remifentanil or fentanyl and propofol both given by TCI. The plasma concentration (Cp) of remifentanil and fentanyl were fixed in each group. The Cp50 of propofol for LOC was determined by up-and-down sequential trial. Cp of propofol was set at 1.25, 1.50, 1.80, 2.16, 2.59, 3.11, 3.73 and 4.48 mg?L-1 . If a patient did not go to sleep at a certain Cp of propofol, the next patient was tested at a higher concentration conversely if the patient went to sleep a lower concentration was tested in the next patient. The BIS values and hemodynamic changes were recorded before induction and at LOC (no response to verbal command and loss of eyelash reflex). The TCI pump was controlled by pharmacokinetic models developed by Marsh (propofol) Minto ( remifentanil) and Shafer ( fentanyl) . Results The Cp of propofol for LOC in group P was 3.48 mg ? L-1 , significandy higher than that in group F (2.31 mg ? L -1 ), group R4 (2.11 mg?L-1) and group R7 (1.76mg?L-1 ) (P

Objective To study the curative efficacy of mometasone furoate aqueous nasal spray combined with loratadine in the treatment of pediatric allergic rhinitis, and its effects on IL-10, IL-17 in serum.Methods 126 patients of pediatric allergic rhinitis who were admitted in our hospital from May 2011 to September 2013 were selected as research objects and randomly divided into treatment group and control group, 63 patients in each group.The control group were treated with loratadine, while the treatment group were treated with mometasone furoate aqueous nasal spray in combination with loratadine.The curative efficacy, scores of clinical symptoms and nasal examination, curing time, medication time and serum IL-10, IL-17 levels were compared between the two groups.Results The total therapeutic efficacy ratio in the treatment group was 98.41%, which was statistically higher than that of 80.95% in the control group (P<0.05).5 weeks after the treatment, scores of sneezing, runny nose, nasal congestion, nasal itching, eye itching and nasal examination in the treatment group were statistically lower than those in the control group (P<0.05).The curing time and medication time in the observation group were statistically shorter than those in the control group ( P <0.05 ) .The inflammatory factors, in comparison with the control group after treatment, the treatment group had statistically higher level of serum IL-10 and lower level of serum IL-17 ( P <0.05 ) . Conclusion Mometasone furoate aqueous nasal spray in combination with loratadine is effective for pediatric allergic rhinitis with a high therapeutic efficacy ratio.And it could significantly improve clinical symptoms, shorten treatment time, increase level of IL-10 and reduce level of IL-17.

Objective To investigate the value of guidance and clinical significance of enteral nutritional support therapy using a joint of nutritional risk screening 2002 (NRS2002) and a screening tool for controlling nutritional status (CONUT) after radical resection of colorectal cancer.Methods The clinical data of 180 patients who underwent radical resection of colorectal cancer at the Tumor Hospital of Xinjiang Medical University between June 2012 and June 2014 were retrospectively analyzed.Seventy patients with scores of NRS 2002 ≥ 3 were allocated into the A group including 40 with enteral nutritional support therapy in the A1 group and 30 without enteral nutritional support therapy in the A2 group, 60 patients with scores of NRS 2002 ＜ 3 and negative CONUT was allocated into the B group including 30 with enteral nutritional support therapy in the B1 group and 30 without enteral nutritional support therapy in the B2 group, 50 patients with scores of NRS 2002 ＜ 3 and positive CONUT was allocated into the C group including 25 with enteral nutritional support therapy in the Cl group and 25 without enteral nutritional support therapy in the C2 group.The nutritional status of patients was evaluated using a joint of NRS 2002 and CONUT.There was nutritional risk in patients with scores of NRS 2002≥3 or scores of NRS 2002 ＜ 3 and positive CONUT and no nutritional risk in patients with scores of NRS 2002 ＜ 3 and negative CONUT.Patients and their families would choose whether or not to undergo enteral nutritional support therapy after the risks being informed.Enteral nutritional support therapy included tube feeding enteral nutrition or oral nutriments with calories ≥41.84 k J/(kg · d) for more than 3 days.Observed indicators: (l)Nutritional indicators included fasting serum albumin (Alb), prealbumin and transferrin before operation, at postoperative day 1 and day 7.(2)Postoperative recovery included time to anal exsufflation, time of defecation, time for semifluid diet intake and duration of hospital stay.Measurement data with normal distribution were presented as x ± s, comparison among groups was analyzed using the t test and repeated measures ANOVA, and count data were analyzed using the chi-square test.Results Patients in A, B and C groups had good tolerance without abdominal pain, abdominal distension and diarrhea.Comparisons of nutritional indicators: the levels of fasting serum Alb, prealbumin and transferrin in the A1 group were (29 ±4)g/L, (0.25 ±0.06)g/L and (2.0 ±0.4)g/L before operation, (27 ±4)g/L, (0.19 ± 0.07) g/L, (1.7 ± 0.4) g/L at postoperative day 1 and (33 ± 5) g/L, (0.27 ± 0.05) g/L and (1.9 ± 0.3) g/L at postoperative day 7, respectively.The levels of fasting serum Alb, prealbumin and transferrin in the A2 group were (29 ±5)g/L, (0.24 ±0.04)g/L and(2.0 ±0.4)g/L before operation, (27 ±4) g/L, (0.18 ±0.05)g/L and (1.7 ± 0.4) g/L at postoperative day 1 and (26 ± 4) g/L, (0.16 ± 0.04) g/L and (1.8 ± 0.5) g/L at postoperative day 7, respectively.There were significant differences in the changing trends of the above 3 indicators between the 2 groups (F =3.256, 6.642, 7.152, P ＜0.05).The levels of fasting serum Alb, prealbumin and transferrin in the B1 group were (37 ± 4) g/L, (0.28 ± 0.05) g/L and (2.0 ± 0.3) g/L before operation, (36 ± 4) g/L, (0.21 ± 0.06) g/L and (1.7 ± 0.5) g/L at postoperative day 1 and (38 ± 4) g/L, (0.30 ± 0.05) g/L and (1.9 ± 0.5) g/L at postoperative day 7, respectively.The levels of fasting serum Alb, prealbumin and transferrin in the B2 group were (36 ±4)g/L, (0.28 ±0.06)g/L and (2.1 ±0.4)g/L before operation, (36 ±3)g/L,(0.23 ±0.04)g/L and (1.7 ±0.4)g/L at postoperative day 1 and (37 ±4)g/L, (0.22 ±0.07)g/L and (1.8 ± 0.5) g/L at postoperative day 7, respectively.There was no significant difference in the changing trends of the above 3 indicators between the 2 groups (F =1.562, 0.625, 2.223, P ＞ 0.05).The levels of fasting serum Alb,prealbumin and transferrin in the C1 group were (28 ± 4) g/L, (0.35 ± 0.06) g/L and (2.1 ± 0.4) g/L before operation, (26 ±4)g/L, (0.17 ± 0.07)g/L and (1.7 ± 0.4)g/L at postoperative day 1 and (34 ± 5)g/L,(0.35 ±0.05)g/L and (1.8 ± 0.3)g/L at postoperative day 7, respectively.The levels of fasting serum Alb,prealbumin and transferrin in the C2 group were(28 ± 5)g/L, (0.34 ± 0.04)g/L and (2.0 ± 0.4)g/L before operation, (26 ± 4) g/L, (0.16 ± 0.05) g/L and (1.7 ± 0.4) g/L at postoperative day 1 and (25 ± 4) g/L,(0.16 ±0.04) g/L and (1.8 ±0.5)g/L at postoperative day 7, respectively.There were significant differences in the changing trends of the above 3 indicators between the 2 groups (F =5.625, 4.225, 8.221, P ＜0.05).Postoperative recovery: time to anal exsufflation, time of defecation, time for semifluid diet intake and duration of hospital stay were (1.9 ± 0.5) days, (2.3 ± 0.5) days, (8.6 ± 1.2) days, (14.7 ± 1.1) days in the A1 group and (3.0 ± 0.5) days, (4.5 ± 0.6) days, (11.4 ± 2.2) days, (17.8 ± 1.3) days in the A2 group, respectively,with significant differences between the 2 groups (t =-0.644,-12.200,-8.710,-11.650, P ＜ 0.05).Time to anal exsufflation, time of defecation, time for semifluid diet intake and duration of hospital stay were (1.2 ± 0.3)days, (3.2 ±0.7)days, (10.3 ± 1.4)days, (14.7 ±2.0)days in the B1 group and (1.5 ±0.5)days, (3.7 ± 0.6) days, (11.0 ± 1.2) days, (16.1 ± 1.5) days in the B2 group, respectively, with no significant difference between the 2 groups (t =-1.929,-1.033,-1.019,-1.171, P ＞0.05).Time to anal exsufflation, time of defecation, time for semifluid diet intake and duration of hospital stay were (1.8 ± 0.7) days, (2.1 ± 0.5) days,(7.6±1.2)days, (13.9 ±1.2)days in the C1 group and (3.1 ±0.5)days, (4.5 ±0.7)days, (11.4±2.4)days,(17.6 ± 1.3) days in the C2 group, respectively, with significant differences between the 2 groups (t =-5.934,-10.950,-10.010,-11.700, P ＜ 0.05).Conclusions A joint application of NRS2002 and CONUT after radical resection of colorectal cancer is exact and feasible for evaluating nutritional status of patients and guiding enteral nutritional support therapy.Patients should select nutritional support therapy after operation if there is nutritional risk.The proper nutritional support therapy can improve the postoperative nutritional status of patients with colorectal cancer, enhance the postoperative recovery and reduce the duration of hospital stay.